# Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

> **NCT03505762** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 80 (actual)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Prednisone
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT03505762
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-19
- **Primary completion:** 2024-03-28
- **Final completion:** 2025-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03505762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03505762, "Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03505762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*